


Fig S2: Change in target lesions from baseline according to PD-L1 status adjudicated by the independent review committee



Responses were assessed in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The upper dashed horizontal line represents progression at 20% increase in size of target lesions, and the lower dashed horizontal line represents the RECIST 1.1 boundary for complete response or partial response at 30% decrease in size of target lesions. Patients with no postbaseline assessment ($n=2$) or no target lesions identified by the independent review committee before first dose ($n=2$) are not displayed. AC, ampullary cancer; CR, complete response; EHCC, extrahepatic cholangiocarcinoma; GBC, gallbladder carcinoma; IHCC, intrahepatic cholangiocarcinoma; PR, partial response.